Improved benefit/risk ratio of higher-dose metoclopramide therapy during cisplatin-induced emesis
Authors:
- 1 January 1985
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 29 (3) , 311-312
Abstract
Metoclopramide (Paspertin) was infused intravenously in the high doses of 1.75, 3.5, 7.0, and 14 mg/kg body wt. per treatment cycle as antiemetic therapy for cisplatin-induced emesis (363 cycles, 25–120 mg/m2). The antiemetic potency of metoclopramide increased in a log linear manner, giving from 40% to 95% protection against emesis. Gas-trointestinal motility showed a similar increase, i.e. diarrhoea. In contrast, the extrapyramidal reactions, namely akathisia, rigidity and acute dystonia, did not show a dose-dependent increase in frequency and remained constant over the dose range of 3.5–14 mg/kg per cycle. The results suggest increasing benefit of metoclopramide treatment with increasing doses of the drug.Keywords
This publication has 5 references indexed in Scilit:
- Metoclopramide kinetics at high-dose infusion rates for prevention of cisplatin-induced emesisClinical Pharmacology & Therapeutics, 1985
- Optimizing Metoclopramide Control of Cisplatin-Induced EmesisAnnals of Internal Medicine, 1984
- DYSTONIC REACTIONS DUE TO METOCLOPRAMIDEThe Lancet, 1984
- Metoclopramide: Pharmacology and Clinical ApplicationAnnals of Internal Medicine, 1983
- MetoclopramideDrugs, 1983